NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

NRX Pharmaceuticals Inc.

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.16% in early trading on Monday. VTI’s three-month...

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/9/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up by 0.30% in pre-market trading on Tuesday. Overall, V...

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/27/26

The Vanguard Total Stock Market ETF ($VTI) tracks the broader U.S. stock market. The ETF saw strong investor inflows last week, signaling renewed i...

VTI ETF Sees $1B Inflows — Are Investors Turning More Bullish?

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is heading down in pre-market trading on Friday. Overall, V...

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/23/26

The Vanguard Total Stock Market ETF ($VTI) is rebounding after a recent sell-off sparked by tariff tensions between the U.S. and the EU. With broad...

VTI ETF Rebounds after Sell-Off — A Quick Snapshot for Investors, 1/22/2026

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NRX Pharmaceuticals (NRXP – Research Report) and Qiagen (QGEN – R...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP) and Qiagen (QGEN)

The Vanguard Total Stock Market ETF ($VTI) tracks the entire U.S. stock market and is widely seen as a solid long-term investment. The fund offers ...

Is VTI a Good ETF? A Quick Snapshot for Investors —1/21/25

NRX Pharmaceuticals ( ($NRXP) ) has shared an announcement. On January 12, 2026, NRx Pharmaceuticals disclosed it had received a Nasdaq notice of n...

NRx Pharmaceuticals Addresses Nasdaq Meeting Compliance Requirements

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.29% in pre-market trading on Wednesday after fall...

Vanguard Total Stock Market ETF (VTI) Daily Update—1/15/25

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NRX Pharmaceuticals (NRXP – Research Report), Olema ...

Analysts Are Bullish on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Olema Pharmaceuticals (OLMA)

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.36% in pre-market trading on Wednesday after fall...

Current Quarter	$-0.09	Next Quarter	$0
Current Year	$-1.45	Next Year	$0.13
QoQ Growth	+100.0%	YoY Growth	+109.0%
3Y EPS CAGR	N/A	Target Price	$36.75
Consensus	Buy	Upside	+1854.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$1.88	-5.53%	365.44K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRXP	$1.88	-5.5%	365.44K
3
4
5
6

NRXP

NRXP

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get NRX Pharmaceuticals Inc. Data in Excel

Get NRX Pharmaceuticals Inc. Data in Excel